These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 24402608

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [Abstract] [Full Text] [Related]

  • 3. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
    Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, Gils A.
    Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309
    [Abstract] [Full Text] [Related]

  • 4. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA, Poolen GC, Koekman CA, Verhoef S, de Maat S, Barendrecht A, van Kleef ND, Meijers JCM, Schiffelers RM, Maas C, Urbanus RT.
    J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.
    Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A.
    Blood; 2011 Apr 28; 117(17):4615-22. PubMed ID: 21343611
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB, Wang W, Bajzar L, Nesheim ME.
    J Biol Chem; 1998 Jan 23; 273(4):2127-35. PubMed ID: 9442053
    [Abstract] [Full Text] [Related]

  • 11. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
    Mishra N, Buelens K, Theyskens S, Compernolle G, Gils A, Declerck PJ.
    J Thromb Haemost; 2012 Jun 23; 10(6):1091-9. PubMed ID: 22498006
    [Abstract] [Full Text] [Related]

  • 12. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C, Stafford AR, Fredenburgh JC, Weitz JI, Gils A, Declerck PJ, Kim PY.
    Thromb Haemost; 2017 Jul 26; 117(8):1509-1517. PubMed ID: 28640323
    [Abstract] [Full Text] [Related]

  • 13. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P.
    Thromb Res; 2000 May 15; 98(4):333-42. PubMed ID: 10822080
    [Abstract] [Full Text] [Related]

  • 14. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.
    Durand A, Chauveau F, Cho TH, Kallus C, Wagner M, Boutitie F, Maucort-Boulch D, Berthezène Y, Wiart M, Nighoghossian N.
    Cerebrovasc Dis; 2014 May 15; 38(4):268-75. PubMed ID: 25401979
    [Abstract] [Full Text] [Related]

  • 15. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO.
    J Biol Chem; 2011 Jan 07; 286(1):502-10. PubMed ID: 21041299
    [Abstract] [Full Text] [Related]

  • 16. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L, Nesheim ME, Tracy PB.
    Blood; 1996 Sep 15; 88(6):2093-100. PubMed ID: 8822928
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis.
    Mochizuki L, Sano H, Honkura N, Masumoto K, Urano T, Suzuki Y.
    Thromb Haemost; 2023 Jan 15; 123(1):16-26. PubMed ID: 36307100
    [Abstract] [Full Text] [Related]

  • 19. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.
    Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN.
    J Clin Invest; 1997 May 15; 99(10):2323-7. PubMed ID: 9153272
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.